VANCOUVER, BC – (Marketwired – June 06, 2017) – NeutriSci International Inc. (the “Company” or “NeutriSci”) (TSX VENTURE: NU) (OTCQB: NRXCF) (FRANKFURT: 1N9), the innovator and pioneer behind neuenergy®, is pleased to announce its first major distribution agreement for neuenergy® into Greater China including Mainland China, Hong Kong, Taiwan and Macau.
Under this agreement, Canada Grand Enterprises Inc. has agreed to act as exclusive distributor for neuenergy® in Greater China. Canada Grand management has more than 40 years’ experience and long-standing business relationships with many of China’s largest retailers, both brick and mortar and online.
Consumer demand for energy products in China is on the rise. According to Beverage Daily, China already represents the largest energy drink market in the world, and has the highest consumption growth rate. As the energy drink and energy supplement market in China continues to grow, so to does the demand for natural alternatives, such as neuenergy®, a revolutionary energy tab designed to deliver enhanced focus and mental clarity with no sugar, no calories and no crash associated with typical energy products.
Mr. Glen Rehman, President of NeutriSci stated, “This distribution agreement represents another major step forward for NeutriSci and neuenergy. This partnership provides consumers local access to neuenergy from trusted retailers throughout China and the surrounding region. The first orders of neuenergy will be leaving our Canadian distribution center for China by the end of June and we expect increasing monthly orders to follow as the product is rolled out. We see this partnership as an anchor in our Asian retail distribution program; driving strong revenues and establishing international brand recognition.”
To find out more about neuenergy®, please visit www.getneuenergy.com.
On Behalf of the Board of Directors of
NEUTRISCI INTERNATIONAL INC.
NeutriSci International Inc.
Tel: (403) 264-6320
About NeutriSci International Inc.: NeutriSci specializes in the innovation, production and formulation of nutraceutical products. Established in 2009, NeutriSci is building sustainable sales models with Convenience, Chain Drug, and Mass Market and Supermarket retailers for neuenergy®, the Company’s natural energy and focus supplement that has at its core, the beneficial effects of blueberries.
Neuenergy® contains a unique patented combination of blueberries (pterostilbene) and naturally derived caffeine, and is a revolutionary energy tab designed to deliver enhanced focus and mental clarity with no sugar, no calories and no crash associated with typical energy products. To find out more about neuenergy®, please visit www.getneuenergy.com.
With the recent formation of Ambarii, a joint venture partnership with Lexaria Bioscience Corp., NeutriSci is expanding its reach into the burgeoning cannabinoid industry.
For more information, please visit: www.neutrisci.com or www.ambariicorp.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward- looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.
Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.